1. Food and Drug Administration, H.H.S., International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice, Fed Regist, 77 (2012) 33748–33749.
2. Appropriate in vivo follow-up assays to an in vitro bacterial reverse mutation (Ames) test positive investigational drug candidate (active pharmaceutical ingredient), drug-related metabolite, or drug-related impurity;Robison;Mutat. Res. Genet. Toxicol. Environ. Mutagen.,2021
3. Detailed review of transgenic rodent mutation assays;Lambert;Mutat. Res.,2005
4. Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing;Hoang;Proc. Natl. Acad. Sci. USA,2016
5. Detection of ultra-rare mutations by next-generation sequencing;Schmitt;Proc. Natl. Acad. Sci. USA,2012